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Nuclear Factor kappa B (NF-κB) is a transcription factor family critical in the activation of pro- in-
ﬂammatory responses. The NF-κB pathway is regulated by oxidant-induced post-translational mod-
iﬁcations. Protein S-glutathionylation, or the conjugation of the antioxidant molecule, glutathione to
reactive cysteines inhibits the activity of inhibitory kappa B kinase beta (IKKβ), among other NF-κB
proteins. Glutathione S-transferase Pi (GSTP) is an enzyme that has been shown to catalyze protein
S-glutathionylation (PSSG) under conditions of oxidative stress. The objective of the present study was to
determine whether GSTP regulates NF-κB signaling, S-glutathionylation of IKK, and subsequent pro-
inﬂammatory signaling. We demonstrated that, in unstimulated cells, GSTP associated with the inhibitor
of NF-κB, IκBα. However, exposure to LPS resulted in a rapid loss of association between IκBα and GSTP,
and instead led to a protracted association between IKKβ and GSTP. LPS exposure also led to increases in
the S-glutathionylation of IKKβ. SiRNA-mediated knockdown of GSTP decreased IKKβ-SSG, and enhanced
NF-κB nuclear translocation, transcriptional activity, and pro-inﬂammatory cytokine production in re-
sponse to lipopolysaccharide (LPS). TLK117, an isotype-selective inhibitor of GSTP, also enhanced LPS-
induced NF-κB transcriptional activity and pro-inﬂammatory cytokine production, suggesting that the
catalytic activity of GSTP is important in repressing NF-κB activation. Expression of both wild-type and
catalytically-inactive Y7F mutant GSTP signiﬁcantly attenuated LPS- or IKKβ-induced production of GM-
CSF. These studies indicate a complex role for GSTP in modulating NF-κB, which may involve S-glu-
tathionylation of IKK proteins, and interaction with NF-κB family members. Our ﬁndings suggest that
targeting GSTP is a potential avenue for regulating the activity of this prominent pro-inﬂammatory and
immunomodulatory transcription factor.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nuclear Factor kappa B (NF-κB) is a family of transcription fac-
tors involved in the regulation of pro-survival, pro-inﬂammatory,
and immune regulatory pathways. Dysregulation of NF-κB has been
linked to a variety of chronic inﬂammatory diseases including
cancer, sepsis, and asthma. NF-κB activity is elevated in lungB.V. This is an open access article u
d Laboratory Medicine, Uni-
enue, HSRF 216A, Burlington,
. Janssen-Heininger).epithelial cells of asthmatic patients in comparison to healthy
controls [1], and activation of classical NF-κB in the lung epithelium
is not only sufﬁcient, but also necessary to regulate airway in-
ﬂammation in mice [2–4]. At least two parallel NF-κB pathways
exist: the classical (canonical) pathway and an alternative pathway
both of which contribute to inﬂammatory responses in lung epi-
thelial cells [5]. In the classical pathway, activation of Inhibitory
kappa B kinase beta (IKKβ) induces the phosphorylation and sub-
sequent degradation of inhibitory kappa B alpha (IκBα), transloca-
tion of RelA/p50 dimers to the nucleus, and transcriptional activa-
tion of over 100 target genes [6]. In the alternative pathway IKKα
phosphorylates p100, which is then partially degraded into p52.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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scription of distinct NF-κB target genes [7].
Given the importance of NF-κB in the regulation of numerous
biological functions, multiple mechanisms exist which tightly
regulate its activation, including oxidant-dependent modiﬁcations.
Thiol groups on protein cysteines with a low pKa are typically
considered susceptible to oxidative modiﬁcations such as S-ni-
trosylation, sulfenic acid formation, disulﬁde bond formation, and
S-glutathionylation [8]. Previous work from our laboratory and
others has demonstrated that NF-κB is modiﬁed via S-glutathio-
nylation, the conjugation of glutathione (GSH) to cysteines via
mechanisms that remain incompletely understood. S-glutathio-
nylation of IKKβ inhibits its kinase activity and downstream pro-
inﬂammatory responses in response to lipopolysaccharide (LPS).
Additionally, S-glutathionylation prevents the ubiquitination and
subsequent degradation of IκBα, as well as the DNA binding of
RelA/p50 dimers [9–12], and is therefore a crucial mechanism of to
regulate the activation of NF-κB.
Our laboratory has previously demonstrated that hydrogen
peroxide-induced S-glutathionylation of IKKβ can be reversed by
the oxidoreductase, glutaredoxin-1 (Glrx1) [9]. We also demon-
strated that overexpression of Glrx1 decreases LPS-induced IKKβ
S-glutathionylation and enhances NF-κB activation, and pro-in-
ﬂammatory cytokine production in lung epithelial cells [13]. While
it is known that Glrx1 can deglutathionylate IKKβ under physio-
logical conditions, the potential enzymatic mechanisms that cat-
alyze IKKβ S-glutathionylation have not been determined. Glu-
tathione S-transferase pi (GSTP), an enzyme traditionally linked to
phase II drug metabolism, is a putative catalyst of protein S-glu-
tathionylation reactions [14–16], and has previously been linked to
asthma [17]. GSTP also associates with TRAF2, a known regulator
of NF-κB [18]. Given the link between GSTP and S-glutathionyla-
tion, the known role for epithelial NF-κB in regulating pulmonary
inﬂammation, and the susceptibility of NF-κB to redox-based
regulation, we sought to explore the role of GSTP in the regulation
of activation of NF-κB in lung epithelial cells exposed to LPS. Our
studies demonstrate a prominent role of GSTP in the regulation of
LPS-driven NF-κB activation and pro-inﬂammatory mediator pro-
duction, which may involve both protein-protein interactions as
well as the catalytic activity of GSTP.2. Materials and methods
2.1. Cell culture and reagents
A spontaneously transformed type II mouse lung alveolar epi-
thelial cell line [19] (C10) was cultured as described previously
[20]. A C10 cell line stably expressing NF-κB luciferase was gen-
erated as previously described [21]. Brieﬂy, C10 cells were trans-
fected with the plasmid, 6 κB-tk-luc, in the presence of the plas-
mid PSV-2Neo (Promega), conferring a resistance to neomycin.
Following incubation with the antibiotic, geneticin, antibiotic-re-
sistant colonies were propagated. C10 cells were starved in med-
ium containing 0.5% FBS for 16 h prior to exposure of 1 mg/mL LPS
(List Biological Laboratories, Inc).
2.2. Plasmids and siRNA
C10 cells were incubated with Dharmacon SMARTpool non-
targeting siRNA or Dharmacon SMARTpool siRNA against murine
GSTP1 (100 nM) (Dharmacon, Lafayette, CO). Plasmid transfections
were performed with Lipofectamine (Invitrogen, Carlsbad, CA).
Wild-type mouse GSTP, Tyrosine 7 Phenylalanine (Y7F) mutant
mouse GSTP, were cloned into PCMV. All transfections utilized a
total of 1 mg/mL DNA unless otherwise indicated.2.3. TLK117 synthesis and treatment
TLK117 is the most speciﬁc GSTP inhibitor to date with a
binding afﬁnity greater than GSH itself and a selectivity for GSTP
over 50-fold greater than the GSTM and GSTA classes (Ki¼0.4 mM)
[22,23]. TLK117 (γ-glutamyl-S-(benzyl)cysteinyl-R-()-phenyl
glycine) was generated by Fmoc solid-state peptide synthesis with
HBTU as previously described [24], and was conﬁrmed to be
498% pure by HPLC. TLK117 was reconstituted in 0.375 M Tris–
HCl, pH¼7.4, containing 0.02% DMSO. C10 cells were pretreated
with 50 mM of TLK117 24 h, and a second time one hour prior to
treatment with LPS. A separate group of cells received 0.375 M
Tris–HCl, pH¼7.4, containing 0.02% DMSO as the vehicle control.
2.4. Western blotting and antibodies
Protein concentration was determined with the Bio-Rad DC
Protein Assay kit (Bio-Rad, Hercules, CA), and 20 mg protein were
used for Western Blot analysis. RelA, RelB, and β-actin antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Antibodies against IκBα, IKKβ, and phosphoserine RelA 536 were
from Cell Signaling Technology (Danvers, MA). IKKα antibody was
purchased from Upstate (Lake Placid, NY), and GSTP antibody was
purchased from MBL (Woburn, MA). Cytosolic and nuclear extracts
were prepared as previously described [25].
2.5. Enzyme-linked immunosorbent assay (ELISA)
C10 cells were treated and/or transfected as indicated, and CCL-
20 and GM-CSF were detected in cell supernatants with Duoset
ELISA kits according to the manufacturer's instructions (R&D Sys-
tems, Minneapolis, MN).
2.6. GSTP activity assay
GSTP activity was determined as previously described [14,24].
C10 cells were harvested in a potassium phosphate buffer con-
taining 0.1% Triton X-100 and protease and phosphatase inhibitors.
Immunoprecipitation of GSTP from cell lysates was performed
with an anti GSTP antibody (MBL) and protein G agarose beads
(Invitrogen). Immunoprecipitated samples were incubated with
5 mM GSH (Fluka, St. Louis, MO) and 1 mM 1-chloro-2,4-dini-
trobenzene (CDNB) (Sigma) and vortexed. Following a 10 min in-
cubation, samples were again vortexed and centrifuged brieﬂy at
14,000 rpm, and supernatant was measured at an absorbance of
340 nm to detect GSH-conjugated CDNB. Results are expressed as
nmol substrate/mg protein/min, wherein one unit represents the
consumption of CDNB per 1 mg of GSTP per minute.
2.7. Detection of protein S-glutathionylation
C10 cell lysates were subjected to immunoprecipitation of GSH-
bound proteins as previously described [26]. Brieﬂy, protein was
isolated with an SDS lysis buffer containing 20 mM N-ethyl mal-
eimide (NEM) (Sigma). 250 mg protein was incubated with 1 mg/mL
anti-PSSG antibody (Virogen, Watertown, MA) and recombinant
protein G agarose beads, and subjected to Western Blot analysis. Prior
to immunoprecipitation, select reagent control samples were in-
cubated with 50 mMDTT for 30 minutes as previously described [24].
2.8. Assessment of luciferase activity
A C10 cell line stably expressing NF-kB-luciferase construct was
utilized to detect NF-kB transcriptional activity. Luciferase units
were normalized to protein content, and results are expressed as
relative luciferase units (RLU) [21].
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Statistical signiﬁcance was determined with GraphPad Prism
v5.0 using either one-way analysis of variance (ANOVA) with a
Bonferroni posttest or an unpaired Student's t-test as indicated. P-
values below 0.05 were considered statistically signiﬁcant. All
experiments were repeated at least two times.3. Results
3.1. Impact of lipopolysaccharide (LPS) on the interaction between
GSTP, IKKβ and IκBα
In addition to its role in phase II drug metabolism, early char-
acterization of GST family members ascribed the term “ligandin” to
reﬂect the capacity of GST to bind to heme or bilirubin [27]. More
recently GSTP has been found to form multiple protein interac-
tions, which in many cases regulate the activity of the target
proteins it binds to [18,28,29]. We therefore ﬁrst sought to in-
vestigate whether an interaction was present between GSTP and
the inhibitor of NF-κB, IκBα, and whether this was affected in cells
stimulated with the NF-κB activator, LPS. In unstimulated cells a
strong interaction was detected between GSTP and IκBα which
was rapidly lost following stimulation of cells with LPS (Fig. 1A).
The LPS-induced loss of interaction between IκBα and GSTP oc-
curred prior to the degradation of IκBα, which is required for NF-
kB activation, and was maintained for at least 24 h following sti-
mulation with LPS (Fig. 1A). Conversely, LPS exposure led to an
interaction between GSTP and IKKβ which ﬁrst appeared between
1 and 2 h and further increased throughout the 24 h exposure
period, and was barely detectable in unstimulated cells (Fig. 1B).
Despite the functional role of IKKα for LPS-induced pro-in-
ﬂammatory responses in C10 lung epithelial cells [5], anIκBα
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overall enzymatic activity in cells (Fig. 2A). LPS-induced nuclear
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luciferase activity was also increased in GSTP siRNA-transfected
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suppression of LPS-induced NF-κB nuclear translocation, tran-
scriptional activity, and production of pro-inﬂammatory
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the control siRNA transfected cells (Fig. 4). Decrease in S-glu-
tathionylation of IKKβ was associated with increases in phospho-
RelA and prolonged decreases in the content of IκBα (Fig. 4), in-
dicative of protracted IKK activation.
3.4. GSTP attenuates LPS-induced or IKKβ-dependent NF-kB activa-
tion and production of pro-inﬂammatory mediators
Given the observed enhancement of LPS-induced NF-kB acti-
vation by GSTP knockdown or inhibition, we next examined
whether GSTP directly regulates LPS-induced pro-inﬂammatory
responses and whether the catalytic activity of GSTP is importantin this regulation. C10 cells stably expressing NF-kB-luciferase
construct were transfected with increasing amounts of FLAG-tag-
ged WT-GSTP, or a version of GSTP containing a Y7F mutation
which is catalytically inactive, or empty vector (PCMV) control
(Fig. 5A and B). Transfection with WT GSTP attenuated LPS-in-
duced NF-κB luciferase activity (Fig. 5C) and GM-CSF content in
the medium (Fig. 5D) in a dose-dependent manner. Surprisingly,
overexpression of Y7F-GSTP mutant also attenuated NF-κB luci-
ferase and GM-CSF (Fig. 5C and D). We further tested the reg-
ulatory role of GSTP for IKKβ-dependent NF-kB activation. C10
cells were transfected with hemeagglutinin (HA)-tagged IKKβ
along with either FLAG-tagged WT-GSTP, or Y7F-GSTP mutant,
or PCMV control (Fig. 5A). Following transfection with WT-IKKβ,
J.T. Jones et al. / Redox Biology 8 (2016) 375–382 381GM-CSF content in the medium was signiﬁcantly increased 24 and
48 h post transfection, compared to cells transfected with control
vector (Fig. 5E). Similar to LPS-induced pro-inﬂammatory re-
sponses, transfection with either WT GSTP or the catalytically in-
active variant of GSTP, Y7F-GSTP, almost completely ablated IKKβ-
induced GM-CSF (Fig. 5E). Overall, these results suggest that cat-
alytic activity of GSTP is not required to attenuate LPS- or IKKβ-
induced NF-κB transcriptional responses.4. Discussion
The airway epithelium plays an important role in inﬂammatory
lung diseases, based upon its roles in barrier function and its in-
terface with cells of the innate and adaptive immune system. GSTP
is expressed in lung epithelial cells [30], which is a prominent
location of NF-κB activation in inﬂammatory lung disease [1,3,31].
In the present study we therefore explored the role of GSTP in
regulating NF-κB activation, S-glutathionylation, transcriptional
activity, and pro-inﬂammatory cytokine production in epithelial
cells exposed to LPS. Our results demonstrate that siRNA-mediated
knockdown of GSTP attenuated S-glutathionylation of IKKβ, and
enhanced NF-κB activation and transcription. Similarly, the isotype
selective inhibitor of GSTP, TLK117, also enhanced NF-κB tran-
scriptional activity. Collectively these ﬁndings demonstrate a role
for endogenous GSTP in attenuating NF-κB transcriptional activity
and production of pro-inﬂammatory mediators in response to LPS.
Results from the present study also suggest that GSTP may pre-
dominantly regulate the canonical NF-κB pathway due to its as-
sociation with IκBα and IKKβ, but not IKKα. Additional studies will
be required to test the impact of GSTP on the alternative NF-κB
pathway, and to address the role of GSTP for the activation of NF-
κB in response to other stimuli.
In addition to its ability to catalyze protein S-glutathionylation
reactions, GSTP can also interact with certain target proteins
through a number of structural motifs. c-Jun N-terminal kinase
(JNK), for example, has been shown to be negatively regulated by
GSTP via direct interaction. Following exposure to either radiation
or exposure to hydrogen peroxide, GSTP oligomerizes and releases
JNK, thus facilitating its activation [29]. GSTP also associates with
and inhibits the function of the adaptor protein, TRAF2. The as-
sociation between GSTP and TRAF2 occurred independent of the
catalytic activity of GSTP, suggesting that GSTP can regulate cel-
lular responses independently of its catalytic activity [18]. It is
therefore plausible that GSTP physically associates with NF-κB
proteins and regulate their function independent of its catalytic
activity. In support of this possibility, both wild-type and cataly-
tically-inactive Y7F mutant GSTP suppressed LPS or IKKβ-induced
levels of GM-CSF and NF-κB transcriptional activity, suggesting
that GSTP can suppress the NF-κB pathway independent of its
catalytic activity.
In the present study, we demonstrated a strong constitutive
association between GSTP and IκBα in unstimulated cells, which
was rapidly lost upon stimulation of cells with LPS, at a time that
preceded IκBα degradation. The constitutive interaction between
GSTP and IκBα could potentially prevent the phosphorylation and
ubiquitination of IκBα, thus preventing NF-κB activation. Our
ﬁndings demonstrate that LPS-induced nuclear content of RelA,
and RelA phosphorylation were increased in cells following siRNA-
mediated GSTP knockdown. Similarly, both GSTP knockdown and
TLK117-mediated GSTP inhibition promoted heightened LPS-in-
duced NF-κB luciferase activity and cytokine production, sug-
gesting a potential regulatory function of GSTP in preventing IκBα
phosphorylation and/or degradation. Previous studies have de-
monstrated that cysteine 189 of IκBα can be S-glutathionylated
and that this decreases phosphorylation by IKK and attenuatesubiquitination in vitro [10], in association with attenuation of its
degradation and subsequent activation of NF-κB [11]. Future stu-
dies therefore will be aimed at unraveling whether associations
between GSTP and IκBα are linked to S-glutathionylation of IκBα,
and whether these events controls activation and or assembly of
the IKK signalsome. As GSTP does not affect IKKβ-SSG until 6 h
post LPS exposure, a time at which NF-κB transcriptional activity is
beginning to subside (data not shown), S-glutathionylation of IKK
proteins may reﬂect a mechanismwhereby GSTP attenuates NF-κB
activity. This putative scenario wherein in the absence of stimulus
GSTP prevents degradation of endogenous IκBα, and a regulatory
mechanism involving GSTP-mediated S-glutathionylation to shut
down IKK activity (graphical abstract) reﬂects a versatile reg-
ulatory mechanism of regulation of NF-κB by GSTP. Additional
studies will be needed to unravel how an NF-κB activating sti-
mulus regulates the protein-protein interactions between GSTP
and various proteins within the NF-κB family, how this function-
ally controls NF-κB activation versus suppression and whether
these events require S-glutathionylation. The oxidant-producing
enzymes that facilitate GSTP-linked S-glutathionylation in epi-
thelial cells stimulated with LPS also remain to be elucidated. It is
now well accepted that activation of NF-κB involves multiple
pathways that encompass multiple kinases, adaptor proteins,
other regulatory post-translational modiﬁcations including ubi-
quitination, chromatin remodeling events, among others, in order
to regulate the transcriptional output of NF-κB. The full spectrum
of interactions between GSTP and these NF-κB pathway compo-
nents and GSTP-targeted S-glutathionylation of these proteins will
require additional redox proteomics studies in order to determine
the precise mechanisms whereby GSTP restricts basal NF-κB ac-
tivity, controls the duration of NF-kB activation, and the repertoire
of NF-κB -dependent target genes affected.
GSTP has been linked to a number of chronic lung diseases,
including asthma, chronic obstructive lung disease (COPD), and
lung cancer [32–34]. The GSTP gene is located on chromosome
11q13, a known locus for asthma-associated genes. Human poly-
morphisms of GSTP, have been linked to atopic asthma; however,
the functional contribution of polymorphic variants disease pa-
thogenesis remain unclear [35,36]. It remains unclear whether the
different GSTP variants differentially control NF-κB activation and
whether this involves protein S-glutathionylation. Of direct re-
levance to the present study are ﬁndings demonstrating that GSTP
inhibits inﬂammation in the ovalbumin model of allergic airways
disease in mice in a strain-dependent manner [37]. However, it
remains unclear whether this inhibitory effect of GSTP on allergic
inﬂammation involved NF-κB or S-glutathionylation chemistry.
In addition to GSTP, other GSTs have been linked to in-
ﬂammatory lung diseases and NF-κB activation. In addition to GSTP,
GSTA and GSTM are also expressed in lung epithelial cells [38]. A
recent study demonstrated that GSTM positive humans display
higher NF-κB activity and airway neutrophilia following allergen
challenge, as compared to GSTM deﬁcient humans [39]. These
ﬁndings are contradictory to the present study which demonstrates
that endogenous GSTP represses NF-κB activity. While GSTM may
have limited S-glutathionylating activity, there are fewer indications
that it possesses the chaperone binding properties of GSTP[40]
Nonetheless, additional studies will be required to elucidate whe-
ther GSTM affects S-glutathionylation of NF-κB pathway compo-
nents, and whether absence of GSTM affects the expression and/or
function of GSTP. Similarly, GSTO also has been linked to the COPD
[41] and can be active in the process of de-glutathionylation [42],
yet its role in the regulation of NF-κB also remains unclear, and
future studies will be needed to address this question.
Herein, we have demonstrated that GSTP modulates NF-κB
activation and pro-inﬂammatory cytokine production in lung
epithelial cells. One potential mechanism by which this occurs is
J.T. Jones et al. / Redox Biology 8 (2016) 375–382382via GSTP-catalyzed S-glutathionylation of IKKβ; however, we also
provide evidence that GSTP associates with NF-κB proteins, no-
tably IKKβ and IκBα. These data suggest multiple mechanisms by
which GSTP regulates NF-κB. Given the reported relevance of GSTP
polymorphisms in allergic asthma, the present ﬁndings which
demonstrate a strong impact of GSTP on the activation of NF-κB
studies provide new insights into the mechanisms by which GSTP
can regulate pro-inﬂammatory signaling in inﬂammatory lung
diseases.Acknowledgments
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